Diurnal Group PLC Notice of Interim Results (1021Y)
March 01 2017 - 1:01AM
UK Regulatory
TIDMDNL
RNS Number : 1021Y
Diurnal Group PLC
01 March 2017
1 March 2017
Diurnal Group plc
("Diurnal" or the "Company")
Notice of Interim Results
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical
company targeting patient needs in chronic endocrine (hormonal)
diseases, will announce its financial results for the six months
ended 31 December 2016 on Monday, 20 March 2017.
For further information, please visit www.diurnal.co.uk
or contact:
+44 (0)20 3727
Diurnal Group plc 1000
Martin Whitaker, CEO
Richard Bungay, CFO
Numis Securities Ltd (Nominated Adviser +44 (0)20 7260
and Joint Broker) 1000
Nominated Adviser: Michael Meade,
Freddie Barnfield, Paul Gillam
Corporate Broking: James Black
Panmure Gordon (UK) Limited (Joint +44 (0) 20 7886
Broker) 2500
Corporate Finance: Freddy Crossley
/ Duncan Monteith
Corporate Broking: Tom Salvesen
+44 (0)20 3727
FTI Consulting 1000
Simon Conway
Victoria Foster Mitchell
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-based specialty pharma company
developing high quality products for the global market for the
life-long treatment of chronic endocrine conditions, including
Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its
expertise and innovative research activities focus on
circadian-based endocrinology to yield novel product candidates in
the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit
www.diurnal.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange
END
NOROKFDDPBKDDBB
(END) Dow Jones Newswires
March 01, 2017 02:01 ET (07:01 GMT)
Diurnal (LSE:DNL)
Historical Stock Chart
From Apr 2024 to May 2024
Diurnal (LSE:DNL)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Diurnal Group Plc (London Stock Exchange): 0 recent articles
More Diurnal Grp News Articles